Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy iShares NASDAQ Biotechnology Index (ETF) (IBB)?

How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don’t always get it right, but, on average, their stock picks historically generated strong returns after adjusting for known risk factors. With this in mind, let’s take a look at the recent hedge fund activity surrounding iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB).

iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) investors should pay attention to an increase in enthusiasm from smart money in recent months. IBB was in 19 hedge funds’ portfolios at the end of September. There were 11 hedge funds in our database with IBB holdings at the end of the previous quarter. At the end of this article we will also compare IBB to other stocks including AerCap Holdings N.V. (NYSE:AER), Staples, Inc. (NASDAQ:SPLS), and Sensata Technologies Holding N.V. (NYSE:ST) to get a better sense of its popularity.

Follow Ishares Trust (NASDAQ:IBB)
Trade (NASDAQ:IBB) Now!

With all of this in mind, let’s go over the recent action regarding iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB).

What does the smart money think about iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB)?

At Q3’s end, a total of 19 of the hedge funds tracked by Insider Monkey were long this stock, a change of 73% from the previous quarter. With hedgies’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were boosting their stakes meaningfully (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Citadel Investment Group, managed by Ken Griffin, holds the largest position in iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB). Citadel Investment Group has a $84 million position in the stock, comprising 0.1% of its 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which holds a $82.4 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Other professional money managers with similar optimism encompass Stephen V. Raneri’s LionEye Capital Management, and Daniel Gold’s QVT Financial.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.